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A commercial Bacillus anthracis (Anthrax) whole genome protein microarray has been
used to identify immunogenic Anthrax proteins (IAP) using sera from groups of donors
with (a) confirmed B. anthracis naturally acquired cutaneous infection, (b) confirmed
B. anthracis intravenous drug use-acquired infection, (c) occupational exposure in a
wool-sorters factory, (d) humans and rabbits vaccinated with the UK Anthrax protein
vaccine and compared to naïve unexposed controls. Anti-IAP responses were observed
for both IgG and IgA in the challenged groups; however the anti-IAP IgG response was
more evident in the vaccinated group and the anti-IAP IgA response more evident in
the B. anthracis-infected groups. Infected individuals appeared somewhat suppressed
for their general IgG response, compared with other challenged groups. Immunogenic
protein antigens were identified in all groups, some of which were shared between
groups whilst others were specific for individual groups. The toxin proteins were
immunodominant in all vaccinated, infected or other challenged groups. However, a
number of other chromosomally-located and plasmid encoded open reading frame
proteins were also recognized by infected or exposed groups in comparison to controls.
Some of these antigens e.g., BA4182 are not recognized by vaccinated individuals,
suggesting that there are proteins more specifically expressed by live Anthrax spores
in vivo that are not currently found in the UK licensed Anthrax Vaccine (AVP). These
may perhaps be preferentially expressed during infection and represent expression of
alternative pathways in the B. anthracis “infectome.” These may make highly attractive
candidates for diagnostic and vaccine biomarker development as they may be more
specifically associated with the infectious phase of the pathogen. A number of B.
anthracis small hypothetical protein targets have been synthesized, tested in mouse
immunogenicity studies and validated in parallel using human sera from the same study.
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Introduction
Bacillus anthracis is a large Gram-positive spore-forming, rod-
shaped bacterium that is the etiological agent of the zoonotic
disease Anthrax. Reservoirs for Anthrax are wild and domestic
ruminants, most commonly sheep, goats, and cattle and their
proximity to humans within an agricultural setting can cause
infection and disease (Dixon et al., 1999). Disease may be
contracted through either direct contact with infected animals,
or within industrialized countries, through contact with animal
by-products such as wool, skins, (Wattiau et al., 2009) or bone
meal, where spores can survive in the environment for decades
(Jernigan et al., 2001; Olano and Walker, 2011). This occurs
when spores enter the body through breaks in the skin, via
ingestion or by inhalation (Little and Ivins, 1999). Cutaneous
anthrax is clearly identifiable by the eschar lesion which appears
sometime after infection at the site of entry, which is usually
self-limiting and treatable with antibiotic therapy (Nalin, 1999).
However, intestinal and inhalational anthrax with severe atypical
pneumonia are by far the most serious forms and can be rapidly
fatal. After a critical turning point, these forms of the disease
no longer respond to treatment and the patient succumbs to
overwhelming septicaemia and toxic shock (Baillie and Read,
2001). This is due to release of various toxins by the Anthrax
bacillus formed of edema factor (EF) or lethal factor (LF) and
protective antigen (PA) (Liu et al., 2014), the genes for which are
carried on a plasmid pXO1. LF and PA combine to form lethal
toxin and EF and PA form edema toxin (Hanna, 1998; Little and
Ivins, 1999), which are responsible for the systemic toxinogenic
effects leading to cell death. Full virulence of B. anthracis requires
additional proteins for capsule biosynthesis encoded on a second
plasmid pXO2 (Mikesell et al., 1983; Turnbull, 1991). The toxin
proteins are in general B. anthracis specific, whereas homologs of
the capsule genes have been found reasonably commonly in other
closely related species. The toxin proteins have as a consequence
been under development by a number of commercial groups as
sub-unit vaccine candidates for Anthrax infection (Brey, 2005;
Splino et al., 2005; Comer and Peterson, 2009; Friedlander and
Little, 2009; Altmann, 2015).
Although Anthrax is primarily a disease of the African and
Asian sub-continents (Dixon et al., 1999) and infection is rarely
encountered in the UK, Western Europe and the USA. It has
made something of a re-emergence in recent years under unusual
circumstances. In 2001 there was an outbreak in postal workers
and other individuals in the USA exposed to letters contaminated
with Anthrax spores (Jernigan et al., 2001, 2002; Dewan et al.,
2002; Perkins et al., 2002). This outbreak lead to infection of
22 individuals with five deaths, whole-scale disruption of the
US postal system for a number of months and was traced to an
incident of deliberate release (Greene et al., 2002; Hadler, 2007).
In addition, there have been a number of more recent infections
in the UK and US associated with contaminated goat skins used
in the manufacture and playing of drums (Anaraki et al., 2008;
Mayo et al., 2010) and the intravenous use of contaminated
heroin (Booth et al., 2010; Hicks et al., 2012; Price et al., 2012;
Grunow et al., 2013; Meghji et al., 2013; Berger et al., 2014;
Veitch et al., 2014). This recent outbreak has to date resulted in
54 infected individuals and 17 deaths. The breakdown of cases
shows 48 confirmed cases and 13 deaths in Scotland (Ramsay
et al., 2010; Palmateer et al., 2012; Booth et al., 2014), five
confirmed cases and four deaths in England (Booth et al., 2010)
and other cases in Europe (Holzmann et al., 2012; Grunow et al.,
2013). Soft tissue infections caused by spore-forming bacteria in
intravenous drug users are not uncommon (Dancer et al., 2002;
Mcguigan et al., 2002; Murray-Lillibridge et al., 2006; Lavender
and Mccarron, 2013; Ascough and Altmann, 2015), but Anthrax
is rare. This cluster of cases is unusual as only one previous case
has been documented in Norway in 2002 (Russell et al., 2013).
This highlights the need for on-going vigilance for detection
of the disease in the community and also for maintenance
and development of methods for screening, surveillance and
protection (Joseph and Read, 2010; Rao et al., 2010).
Testing for rare pathogens is conducted by specialist reference
laboratories within the UK and tests include a combination of
classical methods e.g., culture, molecular and serological assays1.
Continued development of specific, rapid microbiological tests
are a research feature of most specialist reference laboratories
and on-going work ensures constant improvement of “in house”
services. Responsibility for Anthrax testing and environmental
surveillance within the UK lies with Public Health England
(PHE) Porton and this establishment has a continuing interest
in Anthrax biology research. PHE Porton also manufactures
the UK licensed Anthrax vaccine (AVP; Anthrax Vaccine
Precipitated) and undertakes Anthrax vaccine research and
development. The diagnostic technologies group at PHE Porton
supports the activities of both these diagnostic and vaccine
development areas. We have been investigating a number of
methods for detection and characterization of B. anthracis and
for identification of candidate markers for further diagnostic and
vaccine development.
To this end we have been researching the use of protein
microarrays as a platform for immune-competent antigen
discovery, using immune and control sera. This method has
been used successfully previously by other groups (Felgner
et al., 2009; Cretich et al., 2010; Schweitzer et al., 2010; Cruz-
Fisher et al., 2011) and for Anthrax vaccine immune sera
using colony blot (Kudva et al., 2005) and immune-proteomics
(Liu et al., 2013). We have used a commercially sourced
B. anthracis whole genome protein microarray [Protoarray™,
Thermofisher (formerly Invitrogen)] for the screening of
immune sera from a number of different human cohorts and
samples from a rabbit model of Anthrax vaccination. These have
been exposed to B. anthracis antigens, either via vaccination
with the current UK Anthrax protein vaccine, natural or
acquired infection. The human subjects are volunteer donors
who have received the UK licensed anthrax vaccine, plus
unvaccinated controls, occupationally exposed workers from a
Belgian wool-sorters factory (suspected pulmonary exposure),
naturally infected Turkish individuals (confirmed cutaneous
anthrax) and individuals in a cohort of intravenous drug users
(IVDU), tested either positive or negative for anthrax infection.
1https://www.gov.uk/government/collections/rare-and-imported-pathogens-
laboratory-ripl
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Our aim is to identify immunodominant protein biomarkers
which can be used as candidates for diagnostic or vaccine
development and development of reagents for further
characterization of the UK AVP Anthrax protein vaccine.
A comparison was made between infected, vaccinated and
control groups to determine if there are immunodominant
antigens expressed during natural infection that are not present
in the current UK vaccine and/or specific for different groups.
Due to the differing routes of infection that these samples
represent it is likely that different antigen complements will be
expressed or that arms of the immune system will recognize
different anthrax antigen profiles as has been observed for
different complex Anthrax vaccines (Brenneman et al., 2011).
Identification of antigens unique to individuals exposed to
Anthrax spores would help facilitate development of new or
more rapid tests, particularly the development of antibody-based
antigen capture technologies (Olano and Walker, 2011) or
vaccine development (Soborg et al., 2009; Ascough et al., 2014).
These new rapid methods may become useful in a clinical setting
(Weile and Knabbe, 2009) where early diagnosis is crucial.
Antigens shared between the vaccinated and exposed groups
could be useful in characterization of the current vaccine and
also for further vaccine candidate selection. The next generation
of Anthrax vaccines will be based on a thorough knowledge of
the interaction between the virulence factors of B. anthracis and
the host immune response (Turnbull, 1991; Brey, 2005).
Here we present results of this pilot Anthrax
immunodominant biomarker identification study. We have
identified a number of statistically significant proteins which
are either specific to individual groups i.e., naturally exposed,
infected individuals or vaccinees, or are shared between the
groups. Group-specific and shared biomarker profiles are
outlined and these have revealed interesting information about
the number and the type of antigens recognized within and
between test groups. These data suggest that a number of
protein antigens are expressed only during infection, as these
are not recognized by vaccinated or control individuals. This
also suggests there are a group of proteins expressed by B.
antracis which are not currently present in the licensed UK AV
vaccine, which would be of value in future diagnostic test and
vaccine development. Detailed characterization of a few select
antigens is also presented and provides an interesting insight
into the transcriptome of virulent B. anthracis in a host infection
environment.
Materials and Methods
Immune and Control Sera
Anthrax Infected, Exposed, Vaccinee, and Control
Human Sera
Vaccinee and control sera were provided by Dr. Sue Charlton
of the Vaccine Research Group (PHE) and had previously been
assayed for the presence of anti-Protective Antigen (PA), anti-
Lethal Factor (LF), and anti-Edema Factor (EF) antibodies,
using Enzyme Linked Immunosorbant Assays (ELISA). There
were six naïve sera and six vaccinated sera of varying titers
for anti-toxin antibodies (2 low, 2 medium, and 2 high), the
samples were anonymized before receipt. Sera were sourced from
known cutaneous Anthrax-infected individuals from Turkey
and occupationally exposed individuals from a Belgian wool-
working factory (Wattiau et al., 2009). Sera were also sourced
from individuals suspected of Anthrax infection from the recent
outbreak in intravenous drug users. These were confirmed
Anthrax positive (AP IVDU) or confirmed negative (AN IVDU)
cases, by either anti-PA and LF ELISA, B. anthracis-specific PCR
or bacterial culture.
Rabbit Live Spore and AVP Vaccine Sera
Duplicate New Zealand White Rabbits were injected
intramuscularly and sub-cutaneously on Day 0 with live B.
anthracis Sterne strain spores (5 × 106 Colony forming units
(CFU)) or AVP vaccine, with a booster on Day 9. Control rabbits
were vaccinated with saline solution only. A test bleed was taken
from each animal 7 days (Day 17) after each exposure to the
requisite vaccine/saline control. Rabbits were then given another
boost on Days 21 and 30 with a second test bleed collected 7
days after the fourth immunization. This was repeated a further
5 times. Hyperimmune sera were prepared from each animal
from a final bleed taken on Day 137 and used in hybridization
experiments to B. anthracis ProtoArrays™.
Assay Methodology
Anthrax Toxin Human and Rabbit Serum ELISAs
The wells of a microtiter plate were coated with 100µl of rPA or
rLF (10µg/ml) diluted in coating buffer (71627 Sigma) covered
with a plate sealer and left for 60 ± 30min at 37 ± 3◦C in
a shaking incubator. The coating buffer was removed and the
plates washed with fresh wash buffer [1 × phosphate buffered
saline (PBS, P5368 Sigma) 0.1% Tween 20 (P5927 Sigma)]. One
hundred micro liters of blocking buffer [wash buffer + 5% fetal
calf serum (FCS, B8655 Sigma)] were added to each well, the
microtiter plate covered with a plate sealer and incubated for a
further 60min at 37◦C in a shaking incubator. This was removed,
washed three times with wash buffer for 1min and then 100µl
of each serum sample added to the microtiter plate. The plate
was covered with a plate sealer and incubated for 60min at 37◦C
in a shaking incubator. Anti-IgG or IgA horseradish peroxidase
conjugated antibodies were diluted 1 in 100 (Human) or 1 in
1000 (Rabbit) and equilibrated at room temperature prior to
use. The sample was removed and the plate washed again three
times with wash buffer. 100µl of diluted HRP conjugated anti-
Human IgG or IgA (anti-human IgG # VX628420, anti- human
IgA # VX627421, both Invitrogen Life Technologies) or anti-
rabbit (HRP conjugated anti-rabbit IgG # ab6759 or anti-rabbit
IgA # ab8510, both Abcam, UK) was added to each well, the
plate was covered with a plate sealer and incubated for 60min
at 37◦C in a shaking incubator, then the conjugate was removed
and the plate washed three times with wash buffer. Twelve
milliliters of TMB substrate (T0440 Sigma) was incubated at
room temperature for 60min then 100µl added to each well.
The plate was covered with a plate sealer and this was left to
incubate without shaking at room temperature for 5min. One
hundred microliters of TMB stop solution (S5814 Sigma) were
added to each well and the plate read using a VersaMax™
ELISA Microplate reader at 450 nm. Data were quantified and
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exported for analysis using the Softmax Pro version 5.2 ELISA
software.
Serum Hybridization to Anthrax Whole Genome
Protoarrays
All parts of the protocol were conducted at 4◦C. Invitrogen
Anthrax ProtoArray slides [Protoarray™, Thermofisher2
(formerly Invitrogen)] were stored at −20◦C, therefore prior to
use arrays were allowed to equilibrate at room temperature to
avoid excess condensation forming. ProtoArrays were therefore
equilibrated at 3–5◦C, then rehydrated with 1 × blocking buffer
(50mM Hepes pH 7.5, 200mM NaCl, 0.08% Triton X-100,
25% Glycerol, 20mM reduced Glutathione, 1.0mM DTT, 1%
Fetal Calf Serum (FCS), equilibrated to pH 7.5-8.0 with 10mM
NaOH), ensuring coverage of the array, in a sealed slide holder
under constant agitation for 1 h. The slides were then aspirated
and carefully washed three times with 1x PBST buffer [1x PBS
(P5368 Sigma) and 0.1% Tween 20 (P5927 Sigma)] containing
1% FCS. The buffer was gently aspirated off and 15mls of diluted
serum added (1:500 dilution in PBST/0.1% Tween 20) and
incubated at 4◦C for 90min under constant gentle agitation. The
slides were then washed three times with 1x PBST buffer, then
hybridized with two fluorescently labeled secondary antibodies
at a 1/1000 dilution for 45min, goat anti-human IgG-Cy3 (#
ab6597 Abcam, UK) and goat anti-human IgA-Cy5 (# 109-175-
011-JIR Jackson ImmunoResearch, West Grove, USA) or goat
anti-rabbit IgG-Cy3 (# ab6939, Abcam, UK) and goat anti-rabbit
IgA alpha chain-DyLight R© 650 (# ab96978, Abcam, UK). The
slides were washed three times with 1x PBST buffer and air dried
under centrifugation for 5min at 3000 rpm (Sorvall Legend RT).
They were then scanned with a GenePix Pro 4200A microarray
scanner (Molecular Devices, Germany). The fluorescent signals
of each channel (Cy3 and Cy5) were quantified and then exported
for further analysis using Bluefuse™ microarray quantification
software (BlueGnome, UK).
Data Analysis
Statistical Processing of ELISA Data
Raw ELISA data were imported into Systat Software (Inc.)
SigmaPlot for Windows version 12.0. Data points were plotted
in graphical format with log10 transformed serum dilution values
on the x-axis and untransformed extinction coefficients on the
Y axis. These were then analyzed using three parameter logistic
regression analyses according to the given formula below. The
intersect corresponding to the midpoint of the slope of curve on
the X axis i.e., X0 was taken as representation of the half maximal
effective serum dilution value (ED50).
y =
a
1+
(
x
x0
)b
“R” Analysis of Distribution of Anthrax ProtoArray
Hybridization Data
All B. anthracis Protoarray serum hybridization output data
were imported into the statistical package “R”3 and visualized in
2http://www.thermofisher.com/en/about-us/invitrogen.html
3http://www.R-project.org/
histogram graphical format (using the hist base function: signal
intensity on the x-axis vs. frequency on the y-axis). Raw data were
then log2 transformed (using the log2 function) and re-plotted to
investigate the distribution of the data. Data were then sorted into
groups according to origin i.e., negative and positive controls and
anthrax-specific features and overlaid on a plot of all transformed
data points.
Analysis of Anthrax ProtoArray Hybridization Data
using GeneSpring GX 12.5
All B. anthracis Protoarray serum hybridization output
data were then imported into the bioinformatics software
Agilent GeneSpring 12.5 (GX 12.5) and downstream analytical
processes conducted using the statistical analysis tools and other
visualization features of this package. Imported raw data were
normalized to the mean of the buffer only control features, then
baseline transformed to the median of all samples. Normalized
data were assigned to their respective groups, filtered on
expression to remove any features with negative intensity values,
then either analyzed using fold-change analysis or Kruskal Wallis
One-Way analysis of variance [ANOVA (asymptotic p ≤ 0.05,
no multiple testing correction) see below], using as baseline the
negative control condition.
K = (N − 1)
∑g
i=1 ni (ri· − r)
2
∑g
i=1
∑ni
j=1
(
rij − r
)2
Individual group comparisons were analyzed using the non-
parametric Mann–Whitney U-test (asymptotic p ≤ 0.05, fold
change cut off ≥ 1.5, unpaired, no multiple testing correction)
U1 = n1n2 +
n1 (n1 + 1)
2
− R1
All other analyses including unsupervised hierarchical cluster
analysis and depictions of raw and processed data using other
visual outputs e.g., Venn diagram comparisons, were conducted
using other GX 12.5 functions using default settings.
Identification and Chemical Synthesis of Anthrax
Peptide Antigens
Anthrax peptides identified from BLAST searches of online
databases (see Table 3), were synthesized chemically at > 95%
purity by Peptide Synthetics, Peptide Protein Research Ltd., UK4.
These were re-suspended in sterile, purified water (or 10–20%
DMSO/sH2O) at a concentration of 2mg/ml prior to use. These
were used to coat ELISA plates at a concentration of 2µg/ml
in coating buffer. Anti-peptide Ig ELISAs were conducted using
the procedures outlined above for the anti-toxin ELISAs but
substituting Pierce protein-free blocking buffer (Life technologies
#37584).
4http://www.peptidesynthetics.co.uk/
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Results
Determination of Anti- Anthrax Toxin Antibody
Responses and Study Group Designation
All human sera were assayed for Anti-PA and LF toxin
component IgG and where possible IgA reactivity by direct
(immobilized antigen) ELISA using well-established protocols.
These were used to confirm prior anti-toxin ELISA screening of
cutaneous Anthrax patients, exposed woolworkers and vaccine
sera using routine diagnostic methods and establish anti-toxin
titers for IgA (See Supplementary Information S1). Anthrax
positive IVDU (AP IVDU) and Anthrax negative IVDU (AN
IVDU) sera were not retested due to insufficient sera remaining
from routine clinical testing. Data given in Supplementary
Information S1 for these latter patients is derived from routine
diagnostic ELISA data. No data are given for anti-toxin IgA titers
for these latter groups.
All human control sera were assigned to their respective
test groups according to geographical recruitment/vaccination
or exposure history and positive anti-toxin titers for the AVP
vaccines (AVPV), Turkish cutaneous Anthrax patient (TCA) and
Belgian wool-sorters (BWS) group. AP IVDU and AN IVDU
were assigned to their respective groups based on prior anti-PA
and anti-LF IgG results and/or Anthrax bacillus culture or PCR
positivity/negativity (Ramsay et al., 2010). All rabbit sera were
assayed for anti-PA and LF IgG titers using established methods,
similar to those conducted for human sera, substituting anti-
rabbit IgG HRP-conjugated secondary detection antibody. These
were assigned to their respective groups on vaccination schedule
history.
Identification of Immunogenic Anthrax Proteins
using Invitrogen Anthrax Whole Genome
Expressed Protoarrays
All immune and control sera were dual hybridized to Anthrax
whole genome ProtoArrays at a standard serum dilution of 1:500
using either Cy3-labeled anti-human or rabbit IgG and Cy5-
labeled anti human or DyLight R© 650-labeled anti rabbit IgA.
The slides were scanned in both channels, the data quantified
and exported for further analysis using the microarray software
Bluefuse™. Cy3 IgG and Cy5/DyLight R© 650 IgA data were
exported and analyzed separately.
Evaluation, Normalization, and Analysis of Protoarray
Ig-Hybridization Data using Non-parametric
Statistical Analyses
Anthrax whole expressed proteome (ProtoArray) slides were
manufactured by Invitrogen and in addition to the 4916
B. anthracis—specific protein features, spotted in duplicate, the
array contains a number of negative and control features. These
comprise a series of negative controls (blank, buffer, empty,
n = 6700 features) and positive controls mainly chemical
or human biological in origin (Alexafluor markers, AntiBiotin,
human IgG, Biotin, BSA, Calmodulin, CMK, GST, anti-Human
IgG, Internal, Kinase, MAPKAP, V5Control). These, plus other
additional features, i.e., two-fold dilution series of the Anthrax
toxins PA, LF and EF, comprise the remaining array spots (n =
2668). Thus in total there are 19200 total features, arranged in 12
rows and 4 columns in a 20× 20 sub-grid configuration.
In order to investigate the frequency and intensity of
distribution of the data and to inform selection of optimum
normalization methods, all combined data were plotted
in histogram format (Supplementary Information S2) and
Figures 1A,B). Raw data for both IgG and IgA human serum
hybridizations were found to not exhibit a normal distribution
(Supplementary Informations S2 A,B). These were then Log2
transformed and found to exhibit a triphasic distribution
(Supplementary Informations S2 C,D). Color coding of
the different feature groups on the array (Supplementary
Informations S2 E–J) revealed non-normal distribution in all
groups, but particularly the negative and positive control groups.
The reasons for these are not known, however some may be due
to technical anomalies (i.e., high fluorescence intensity of the
FIGURE 1 | (A) Log2 frequency of distribution of fluorescence intensities of all
protein, positive and negative control array entities using Cy3 labelled
anti-human IgG antibody. (B) Log2 frequency of distribution of fluorescence
intensities of all protein, positive and negative control array entities using Cy5
labelled anti-human IgA antibody. All combined data B. anthracis protein
entities H. sapiens control protein entities (Alexa, AntiBiotin, Anti-human
IgG, Biotin, BSA, Calmodulin, CMK, GST, Human IgG, Internal, Kinase,
MAPKAP, V5Control) features labelled as ‘empty’ on the array features
labelled as ‘blank’ on the array features labelled as ‘buffer’ on the array.
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“empty” and “blank” controls), or due to specific (anti human
IgG) or non-specific (MAPKAP) Ig binding to these features.
However, these are not useful in analytical interrogation of
the array and may have the effect of skewing standard default
normalization and baseline transformation processes (e.g., to
default 75th percentile and median of all samples). They also
dominate downstream statistical analyses based on p-value
ranked datasets. Although the B. anthracis-specific features also
show a similar distribution pattern, this was less pronounced. It
was therefore decided to filter the data to remove all extraneous
controls with the exception of the “buffer” only and continue
analysis using these and the B. anthracis-specific features
(including toxins) only. Non-parametric statistical tools were
used for all downstream analytical processes.
Sorted raw data (replicate data-points) for B. anthracis-
specific features and buffer only, from both IgG and IgA
ProtoArray hybridizations using sera from all human groups
were imported into GX12.5, normalized to the average of
buffer only control features, then baseline transformed to the
median of all samples as described above. All entities were
then filtered on expression and then analyzed using either the
non-parametric Kruskal-Wallis One-Way ANOVA (no multiple
testing correction and an asymptotic corrected p-value cut-off
of p ≤ 0.05) or Mann–Whitney U-test analyses (unpaired, no
multiple testing correction, at a fold-change cut off≥ 1.5 and p ≤
0.05). Data were then analyzed further and depicted graphically
using other functions in GX 12.5.
Data Statistical Analysis of Normalized Human
Protoarray Ig-Hybridization Data using
Non-parametric ANOVA
All human IgG and IgA hybridization data were analyzed using
Kruskal–Wallis One-Way ANOVA as described above, 6556 of
9706 (67.6%) features were positive for recognition by IgG and
1789 (18.4%) for IgA. The data were ranked on p value; the top
ranked differentially recognized hit for IgG was EF (0.78125
ng/µl concentration, with the 0.360295 ng/µl concentration at
position 5). These plus other EF features are strongly recognized
by the AVPV group and not by the AP IVDU or the TCA
groups. Other toxin features also figured strongly in the top 100
entities at various dilutions (data not shown), along with other
B. anthracis proteins. The top ranked differentially recognized
hit for IgA was not EF which appeared at position 15 (0.78125
ng/µl concentration). This feature again appeared to be more
specifically recognized by the AVPV and also the BWS groups
and not the AP IVDU, AN IVDU or the TCA groups. Other
toxin dilution features did not feature strongly in the top ranked
100 for IgA. This may be due to the fact that these are recognized
less strongly overall by IgA compared with IgG. However, there
is clear differential recognition of the toxin components in the
different groups and in particular the AVPV and AP IVDU and
TCA groups for both IgG and IgA as seen in Figure 2. Cluster
2c in Figure 2I and cluster 2a in Figure 2II contain the majority
of the toxin features and exhibit clear differential recognition
between groups (discussed in further detail in SectionMicroarray
Investigation of Human IgG and IgA Anti- Anthrax Toxin
Features and Identification of B. anthracis-specific Hypothetical
Proteins and Peptide ELISA Analysis of Human Sera
below).
Of these statistically significant entity lists, 1080 (T1080) were
shared between the IgG and IgA datasets [see Supplementary
Information S3). Unsupervised Euclidean hierarchical cluster
analyses for the T1080 feature list for IgG and IgA data are
shown in Figure 2. Overall there is high IgG recognition of many
protein entities by the naïve control group; most likely due to
recognition of common shared eubacterial proteins from prior
exposure. However unusually, recognition of the total number of
proteins by control sera do appear to be in excess of those seen
for all other groups. There appears to be particularly reduced
recognition of protein features by the infected AP IVDU and
TCA groups, which is most pronounced for IgG and less so for
IgA. This is particularly evident in the TCA group which shows
very restricted protein recognition repertoire for IgG. This is also
evident in cluster analysis of the complete unfiltered IgGANOVA
dataset (data not shown). However, in the IgA dataset there is
good recognition of proteins by all groups, yet the repertoire
of proteins recognized is different. The recognition profiles of
the AP IVDU, AN IVDU, and TCA are highly similar, whereas
the AVPV and BWS profiles are alike. Using Hierarchical cluster
analysis on both conditions and entities on the IgA ANOVA
data, the AP IVDU, AN IVDU, TCA, and control groups co-
cluster together, with the AP IVDU, AN IVDU in one sub-
cluster and the TCA and control group in a second sub-cluster,
whereas the AVPV and BWS associate separately (data not
shown). This indicates similar recognition profiles between the
AP IVDU, AN IVDU, and the TCA and control group. The
profiles of proteins are clearly different between the clusters.
Similar analyses using the IgG data (data not shown) revealed
that the AP IVDU and TCA groups co-cluster together, with
the remaining groups clustering separately. Thus highly similar
recognition profiles for IgG are seen for the AP IVDU and the
TCA groups with very restricted repertoires, the TCA group
overall exhibiting the most restricted IgG protein repertoire
recognition. IgG recognition of proteins in the infected groups
appears depressed, whereas IgA recognition of proteins is less
depressed but exhibits group-specific restricted repertoires, with
some groups showing similarities.
Comparative Non-parametric T-test Statistical
Analysis of Normalized Human Protoarray
Ig-hybridization Data and Identification of Group
Specific Antigens
To further delineate some of the differentially recognized features
(DRF) between the control and test groups, non-parametric
Mann–Whitney U-test analyses were conducted between the
control and each of the individual test groups (Supplementary
Information S4) for both IgG and IgA hybridization data.
These revealed for the IgG data (a) 8 entities DRF for the
BWS, including the 3 lowest PA and 2 lowest LF concentration
features, plus BA1930, BA0973 and BA2389 and 297 DRF for
the control [Supplementary Information S4 Figure A (i)] (b) 4
entities DRF for the AN IVDU, including BA2377 (duplicate
features), BA2389 and BA5591 and 1255 DRF for the control
[Supplementary Information S4 Figure A (ii)] (c) 3 entities
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FIGURE 2 | Unsupervised Euclidean hierarchical cluster analysis of shared T1080 hits between IgG positive and IgA positive ANOVA entities. (A), IgG
data set (B), IgA data set.
DRF for the AP IVDU including PA 200 ng/µl concentration
and BA4182 (duplicate features) and 1990 DRF for the control
[Supplementary Information S4 Figure A (iii)] (d) 27 entities
DRF for the AVPV including 27/30 of the PA, LF, and
EF concentrations (excluding the EF 200, PA 0.78125, and
0.390625 ng/µl concentrations) and 1582 DRF for the control
[Supplementary Information S4 Figure A (iv)] (e) 13 entities
DRF for the TCA including 9/10 of the LF concentrations and
the top four concentrations of PA (200, 100, 50, and 25 ng/µl)
and 6773 DRF for the control [Supplementary Information S4
Figure A (v)]. Supplementary Information S4 Figure A (vi)
shows a comparison between the Anthrax positive groups of
all statistically significant entities which bar 4 are all toxin
component features. Remaining group-specific entities are given
in Supplementary Information S4 Table 1.
Similar analyses for the IgA data revealed (a) 123 entities DRF
for the BWS, with no positive toxin features and 737DRF for
the control [Supplementary Information S4 Figure B (i)] (b) 8
entities DRF for the AN IVDU and 321DRF for the control
[Supplementary Information S4 Figure B (ii)] (c) 18 entities
for the AP IVDU, again including BA4182 [see Supplementary
Information S4 Figure B (vii) and Supplementary Information
S5] and PA (50 ng/µl concentration) and 437DRF for the
control [Supplementary Information S4 Figure B (iii)] (d) 80
entities DRF for the AVPV including EF (0.78125 ng/µl) and LF
(0.390625 ng/µl) and 2378DRF for the control [Supplementary
Information S4 Figure B (iv)] (e) 3 entities for the TCA
including BA2967 and BA3953 and 275 DRF for the control
[Supplementary Information S4 Figure B (v)]. Supplementary
Information S4 Figure B (vi) shows a comparison between the
Anthrax positive groups of all statistically significant entities.
Group-specific entities are given in Supplementary Information
S4 Table 2.
Similar analyses were conducted between the clinical infected
TCA and AP IVDU groups to identify antigens which may be
differentially recognized (U-test data outputs depicted in scatter
plot graphical output in Figures 3, 4). One hundred and fourteen
DRF for the TCA and 650 DRF for the AP IVDU were found
between the groups for the IgG data and 268 DRF for the
TCA and 244 DRF for the AP IVDU were found between the
groups for the IgA data. However, many of these entities are
also recognized by other groups. All entity lists were further
interrogated on an individual entity basis for group-specific DRF
which are outlined in detail in Supplementary Information S6
Tables 1, 2.
Microarray Investigation of Human IgG and IgA Anti-
Anthrax Toxin Features
The Anthrax ProtoArray contained spotted features of two-
fold dilutions of each of the toxin components PA, LF, and
EF (concentration ranges from 200 to 0.390625 ng/µl i.e., 10
features per toxin subunit). These features were extracted and
investigated separately (Figure 5) for both IgG and IgA to
compare recognition of the toxins between different groups. This
revealed for IgG (1) strong recognition of all dilutions of all
three toxin components by the AVPV group, in a gradient with
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FIGURE 3 | Scatter plot depiction of statistically significant IgG
recognized entities using a Mann–Whitney U-test (unpaired, unequal
variance, p < 0.05, fold change cut-off 1.5) between the IVDU Anthrax
positive and the Turkish cutaneous Anthrax patient groups.
Highlighted immunogenic, differentially recognized protein entities A to I are
given in detail in Supplementary Information S6 Table 2.
preferential recognition of the lowest toxin concentrations (2)
reduced recognition of PA and LF by the AP IVDU and TCA
groups (but very low recognition of EF), in a gradient with
preferential recognition of the highest toxin concentrations (3)
weaker recognition of all toxins for the BWS group, with a graded
preference toward lower concentrations for EF and PA and a
two-phase gradient of recognition for LF (4) some evidence of
recognition of EF and PA by the control and AN IVDU groups
and LF by the control group, but this is low and may represent
background level recognition.
In addition for IgA (1) weak recognition of all dilutions of
all three toxin components by the AVPV group, in a gradient
with preferential recognition of the lowest toxin concentrations
(2) strong recognition of PA and LF by the AP IVDU and
TCA groups (with very low recognition of EF by the AP IVDU
group, but recognition of EF at the higher concentrations for
the TCA group), in a gradient with preferential recognition of
the highest toxin concentrations (3) very weak recognition of all
toxins for the BWS group, with a graded preference toward lower
concentrations for EF, PA, and LF. There was some evidence of
recognition of EF by the control and AN IVDU groups and some
background recognition of PA and LF by the control group.
Thus, the infected and vaccinated groups demonstrate good
recognition of two or more of the toxin components, with
IgG recognition bias for AVP vaccinated individuals and IgA
recognition bias for Anthrax infected individuals. The BWS
group exhibited unbiased IgG and IgA recognition of toxin
components.
Comparative Investigation of Microarray Human
and Rabbit Igg and Iga Anti- Anthrax Toxin
Features
New Zealand white rabbits were vaccinated with B. anthracis
Sterne live spore vaccine (LSV) or AVP protein vaccine according
to the above protocol (see Section Rabbit Live Spore and AVP
Vaccine Sera). All spore and AVP vaccinated rabbits gave good
anti-PA and LF IgG titers (data not shown). Final bleed sera were
hybridized to the Anthrax ProtoArray according to the same
protocol for all human sera (see Section Serum Hybridization
to Anthrax Whole Genome Protoarrays) and data processed
and imported into GX 12.5 according to the protocols outlined
above. Due to the small sample size full statistical processing was
not conducted, however fold change analysis (FC cut-off >25)
on normalized, baseline transformed IgG and IgA data revealed
all toxin components to rank as the top hits (data not shown).
A number of other Anthrax proteins were also detected above
this threshold, however none were found to be shared with the
human datasets. Fold-change values of the toxin components
and relative comparison of the fold-change difference between
spore and vaccinated rabbit data are given in Supplementary
Information S7.
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FIGURE 4 | Scatter plot depiction of statistically significant IgA
recognized entities using a Mann–Witney U-test (unpaired, unequal
variance, p < 0.05, fold change cut-off 1.5) between the IVDU Anthrax
positive and the Turkish cutaneous Anthrax patient groups.
Highlighted immunogenic, differentially recognized protein entities J–Q are
given in detail in Supplementary Information S6 Table 2.
Combined boxplot depictions for normalized toxin data
outputs (for all toxin components and concentrations) are
given in Figure 6. For comparison analogous human data
outputs are given in Figure 7. Good reactivity to all toxin
component dilutions was seen in each of the rabbit vaccination
challenge groups for both IgG and IgA, when compared to
the unvaccinated control. It is apparent that AVP vaccinated
rabbit’s exhibit a higher anti-toxin IgG response than for LSV
vaccinated rabbits, which in turn is above that of the control
saline vaccinated rabbits. Conversely, LSV vaccinated rabbits
exhibit a higher IgA anti-toxin response than AVP vaccinated
rabbits which in turn is above that of the control saline vaccinated
rabbits. This observation is paralleled in the human sera data,
where the AVPV group exhibits a higher anti-toxin IgG response
than the naturally infected AP IVDU and TCA groups, which
conversely exhibit a higher anti-toxin IgA response than the
AVPV group. The lower threshold for the AP IVDU and TCA
group IgA data appears somewhat reduced compared with that
for the AVPV IgG response, due to a lack of anti-EF response
in these groups, whereas recognition of all toxin component
dilutions by IgA is reduced overall in the AVPV group. Thus, live
spores through natural infection appear to elicit an IgA biased
response, in contrast to that generated through AVP protein
vaccination, which exhibits IgG bias. The BWS group exhibit
similarities to the AVPV group, perhaps suggesting primary
exposure to protein antigen not live spores.
Identification of B. anthracis-specific
Hypothetical Proteins and Peptide Elisa Analysis
of Human Sera
Many of the proteins identified in this study although highly
immunogenic and/or exhibiting some specificity for individual
groups, were found to either not exhibit B. anthracis specificity
using BLAST interrogation of online bioinformatics databases
or were too large for on-going analysis, without complex
cloning, expression and purification. We wished to identify
Anthrax specific peptides which exhibited B. anthracis species-
specificity and were also of a size amenable for chemical synthesis
for downstream testing for either vaccination or diagnostic
purposes. To this end all annotated B. anthracis “hypothetical”
and “conserved hypothetical” proteins identified from online
databases were compared to all deposited protein and nucleic
acid sequences using the BLASTP and tBLASTn5 functions
of online database search algorithms (data not shown). Five
proteins were selected from these analyses, two of which
exhibit complete sequence specificity for B. anthracis, BA2182
and BA0448, two which exhibit partial sequence specificity
BA2157 and BA1695 and one control protein exhibiting extensive
sequence conservation with closely related bacillus species
BA4898 (Table 3). Only BA0448, BA1695 and BA4898 are
represented on the Anthrax ProtoArray. All these peptides were
5http://blast.ncbi.nlm.nih.gov/Blast.cgi
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TABLE 1 | B. anthracis-specific and other partially conserved immunogenic protein entities identified by sequence comparison of all B. anthracis
hypothetic proteins with database sequences using BLAST.
Gene name Name Peptide sequence/alignment to nearest neighbor % Similarity GroupIg
positivity
p-Value
human IgG
p-Value
human IgA
BA2157 Hypothetical protein
(B. anthracis)
MSKNETVLLNQIEIVIEIFKNIQKVDPFYKDL
MSKNETVLLNQIEIVIEILKNIQKEDPFYKDL
94 NA NA NA
BA2182 Hypothetical protein
(B. anthracis)
MDYVENNRIHFQHTKRKLESFQLPFFFTEQYLI 0 NA NA NA
BA1695 Hypothetical protein
(B. anthracis)
MLYEETIYHFDCI SFLSNECLGRIYRIEKNDEQAI
MLYEETIYHFDRKSFLPHERLGRICEIEKNDEQAI
80 Turkish (IgA) ND 1.16×10−1
BA0448 hypothetical protein
(B. anthracis)
MKRIGINDKCIGCGAEVDDPECECEWRTCSCCGYPDCF
VYEEGRYYHCKNCDHSTDPGHY
0 Belgian and
Turkish (IgG)
Turkish (IgA)
9.1× 10−3 1.64×10−2
BA4898 Small, acid-soluble
spore protein (sspB)
MARSTNKLAVPGAESALDQMKYEIAQEFGVQLGADAT
MSRSTNKLAVPGAESALDQMKYEIAQEFGVQLGADAT
ARANGSVGGEITKRLVSLAEQQLGGFQK
ARANGSVGGEITKRLVSLAEQQLGGFQK
98 Turkish (IgA) ND 4.02×10−2
TABLE 2 | IgG Anti-PA, LF and immunogenic peptide (from Table 1) ELISA data.
Antigen C AVPV TCA AP IVDU
EC50 Standard error R EC50 Standard error R EC50 Standard error R EC50 Standard error R
PA NA NA NA 300.233 145.975 0.9311 NA NA NA 157.512 112.115 0.758
LF NA NA NA 89.822 90.534 0.908 NA NA NA 69.577 62.239 0.915
BA2157 NA NA NA NA NA NA NA NA NA NA NA NA
BA2182 NA NA NA NA NA NA NA NA NA NA NA NA
BA1695 NA NA NA NA NA NA NA NA NA NA NA NA
BA0448 NA NA NA NA NA NA NA NA NA 25.221 77.188 0.867
BA4898 NA NA NA NA NA NA NA NA NA NA NA NA
EC50 (χ0 ), standard error and R-values are given from three parameter logistic regression analysis.
chemically synthesized and then used to screen control and
immune sera from the AVPV, AP IVDU, and TCA groups, using
established ELISA protocols in comparison to PA and LF as
positive controls.
It can be seen that none of the five peptides were recognized
by IgG in the AVPV and TCA groups and only BA0448 was
recognized by the AP IVDU group. LF and PA were recognized
at high titer in the AVPV and AP IVDU groups, however
there was some response to LF and PA in the TCA group, but
no three parameter logistic regression curve could be fitted to
this data. R-values indicate greater consistency of recognition
of LF in the AP IVDU group and that BA0448 exhibits better
efficiency of detection than PA, whereas equivalent consistency
of recognition of PA and LF is seen in the AVPV group. All
5 peptides were recognized by IgA in the AP IVDU and TCA
groups and 4 of 5 were recognized by the AVPV group, with the
exception of BA2182. R-values indicate again greater consistency
of recognition of LF in the AP IVDU group and that all peptides
exhibit better efficiency of detection than either LF or PA, whereas
recognition of PA and the peptides appear less consistent than
LF in the AVPV group. Consistent recognition of either toxin
or peptides was not observed in the TCA group, indicating
some variability between individual recognition profiles for these
antigens. Thus the peptides may offer improved diagnostic
detection capability in the AP IVDU group, particularly BA0448.
These peptides were also tested in mouse vaccination studies,
however none proved immunogenic in an adjuvant-augmented
prime, dual boost vaccination strategy (data not shown),
indicating that individually these peptides are not inherently
immunogenic as synthetic peptides i.e., in the absence of either
other proteins in a complex protein vaccine (i.e., AVP), or in an
infection setting.
Discussion
Sera sourced from a number of suspected and/or confirmed
Anthrax infected, UK AVP vaccinated or negative control groups
were assessed for their anti-PA and anti-LF Ig responses by
ELISA, for IgG and where possible IgA, to confirm or exclude
prior Anthrax antigen exposure. Similar confirmatory analyses
were conducted for sera from a rabbit vaccination model using
the veterinary B. anthracis Sterne strain live spore or UK AVP
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FIGURE 5 | Fluorescence intensity of B. anthracis anti-toxin IgG (I)
and IgA (II) responses for edema factor (EF), Lethal factor (LF) and
Protective antigen (PA) and buffer only control (B). A concentration
gradient from 200 to 3.125 ng/µl was spotted on the array for each toxin
protein, indicated by the block arrowheads, from highest (top) to lowest
(bottom) concentration. (A) Negative controls (B) IVDU Anthrax negative (C)
IVDU Anthrax positive (D) AVP vaccinees (E) Belgian Woolsorters (F) Turkish
cutaneous Anthrax patients.
vaccines. All immune and control sera were then hybridized to
the Invitrogen Anthrax ProtoArray.
Combined data outputs from these hybridization experiments
were evaluated by plotting untransformed and transformed
distribution curves and found to exhibit a non-normal (triphasic)
distribution. These distribution curves were found in the main
to be influenced by high background values from “empty” and
“blank” negative controls and the diverse range of “positive
control” features, unrelated to the B. anthracis protein feature
content of the array. High intensity values from these controls
had the effect of biasing on-going data analyses both with normal
data normalization procedures and when interrogating ranked
data sets for statistically significant features. This necessitated
the removal of the B. anthracis protein features and “buffer”
only controls, which were then analyzed separately. Filtered data
sets were then imported into the bioinformatics software GX
12.5 using normal procedures and henceforth analyzed using
non-parametric data analysis tools.
Kruskal Wallis non-parametric ANOVA analyses revealed a
large number of proteins recognized by IgG (67.6%) across all
the human groups and fewer for IgA (18.4%). This is confirmed
from the distribution curve data (Figure 1), where we see that
there is a higher frequency of low intensity IgA- recognized
protein features than those observed for the IgG-data. Thus,
overall more proteins are recognized by IgG than IgA across
all the human groups. However, this seems to be found mainly
in the control group, which appear to exhibit recognition of
a very large number of protein features compared with the
other immune groups. U-test analyses between the control and
all other groups confirmed this observation. This is somewhat
unexpected and while it would be perhaps expected that
unvaccinated/challenged individuals would exhibit recognition
of a proportion of the proteins represented on the array due to
immune memory to cross-reactive, conserved bacterial proteins,
the large number of these recognition events is surprising.
However, similar results have been observed for a previous
study on Bulkholderia pseudomallei infection (Felgner et al.,
2009), with normal uninfected control sera exhibiting cross-
reactive recognition of bacterial species-specific proteins. These
were previously suggested to be due to prior exposure to the
organism; however it may be in the main due to recognition
of conserved bacterial protein epitopes from other unrelated
bacterial infections. This requires further investigation.
Another striking observation was the apparent reduced
protein repertoire recognition by IgG of many proteins on the
array for the AP IVDU and TCA infected groups, particularly
for the latter. However, there is some recognition of the toxin
and other protein features by IgG, along with a limited number
of other proteins. This is an interesting observation and is
supported by previous studies which suggest that B. anthracis
spores, capsule and toxin target immune cells to dismantle the
immune system (Baldari et al., 2006; Oliva et al., 2008; Hu
and Leppla, 2009; Jelacic et al., 2014). In particular LF toxin
and B. anthracis spores may specifically target B-cells (Fang
et al., 2006; Lightfoot et al., 2014; Sahay et al., 2014). B-cells
may also be implicated as the primary cell type involved in
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FIGURE 6 | Box plot graphs of combined array anti-toxin responses
across all toxin concentrations for the rabbit spore and AVP
vaccinated and control groups (A) IgG (B) IgA.
dissemination of the bacillus from the lung during inhalational
Anthrax (Rayamajhi et al., 2012). Quinn and co-workers showed
that a significant proportion of cutaneous Anthrax patients with
presumed long-term chronic infection showed no memory B-
cell IgG response to PA, whereas acutely infected inhalational
Anthrax patients retained B-cell anti-PA IgG immune memory
(Quinn et al., 2004). This may imply that the memory B-cell
response is abrogated by Anthrax infection, particularly during
chronic infection and this is supported by the results presented
in this study.
This effect was less pronounced for IgA in both the AP IVDU
or TCA groups and this does not appear to be due to intravenous
drug use in the former group, as this effect is not seen in the
AN IVDU group. The anti-toxin response is more pronounced
for IgA in these infected groups. These perhaps constitute a de
novo response to the infectious agent, after prior infection and
subsequent to an apparent near eradication of the memory IgG
response (although there is a moderate anti-toxin IgG response
in these groups also). Despite evidence of this anti-Anthrax
humoral response, this is not protective and appears insufficient
to remediate on-going clinical infection, as these patients were
FIGURE 7 | Box plot graphs of combined array anti-toxin responses
across all toxin concentrations for each of the human test and control
groups (A) IgG (B) IgA.
confirmed to be infected on sample collection (by culture) and
many exhibited severe disease in the AP IVDU group. Many of
these IVDU succumbed to the disease and those in the TCA
group required antimicrobial therapy.
A number of proteins were recognized by both IgG and IgA
(T1080) and cluster analyses revealed group-specific recognition
of proteins by both IgG and IgA; however recognition of
some proteins was shared between groups. This also showed
differential recognition of the toxin components between the
groups. Cluster analyses revealed similarities between the
recognition profiles of key groups i.e., the AP IVDA and TCA
groups co-clustered together on the basis of IgG recognition
profiles, whereas the remaining groups clustered together. The
view for IgA was somewhat different. In both analyses the AP
IVDU and TCA groups always segregate together as do the
AVPV and BWS groups, indicating broadly similar recognition
profiles. This may be taken to imply a common route of exposure.
The AVPV and BWS groups being highly similar have perhaps
received exposure through cutaneous contact to protein, whereas
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TABLE 3 | IgA Anti-PA, LF, and immunogenic peptide (from Table 1) ELISA data.
Antigen C AVPV TCA AP IVDU
EC50 Standard R EC50 Standard R EC50 Standard R EC50 Standard R
error error error error
PA 2.257 24.704 0.827 17.425 49.059 0.867 22.196 53.151 0.837 338.341 450.497 0.652
LF NA NA NA 15.581 36.649 0.911 0.859 9.311 0.868 49.165 72.961 0.889
BA2157 NA NA NA 14.40 75.286 0.772 121.926 152.2116 0.749 109.596 55.105 0.968
BA2182 NA NA NA NA NA NA 60.135 105.842 0.769 43.687 61.736 0.967
BA1695 NA NA NA 24.163 103.353 0.778 182.563 275.875 0.629 3.96 14.627 0.955
BA0448 NA NA NA 18.274 58.081 0.846 100.593 109.026 0.795 86.747 48.249 0.967
BA4898 NA NA NA 8.1610 49.5106 0.8073 34.8602 65.8659 0.8348 6.6059 27.3280 0.9064
EC50 (χ0 ), standard error and R-values are given from three parameter logistic regression analysis.
in the AP IDVU and TCA groups, exposure is to Anthrax
bacilli. This appears to drive very different immune recognition
responses, which is dominated by the IgG response in AVP
vaccines and by IgA in individuals exposed to live spores.
Mann–Whitney U-test analyses of the control versus all
other groups revealed a large number of proteins recognized
by the control group in comparison to the test groups. Again,
as discussed above the recognition of such a large number
of proteins by this group is unexplained and further work
is required to investigate the origin of this phenomenon.
However, there was consistency between the control and all
other groups for both IgG and IgA protein recognition profiles.
Differentially recognized proteins in the test groups compared
to the control comprised mainly different dilution features of
the toxin components and a limited number of other protein
features. Some of these are group specific. Many of these
identified additional proteins were not found to be B. anthracis-
specific with homologs in other closely related bacterial species.
However, some are of interest biologically and warrant further
investigation with regard to their specific role in infection and/or
their use in on-going vaccine or diagnostic test development. One
protein in particular BA1482 (See Supplementary Information
S5) or pdhC (pyruvate dehydrogenase complex E2 component,
dihydrolipoyllysine-residue acetyltransferase) is of particular
note and is strongly and specifically recognized by IgG in the
AP IVDU group and by IgA in the AP IVDU and TCA groups.
This protein may be highly expressed during the infectious
process and recognized de novo by the humoral antibody
immune response. Components of the pyruvate dehydrogenase
complex have been shown to be involved in pathogenicity
in other bacterial species such as Mycobacterium tuberculosis,
particularly in latency and persistence (Bryk et al., 2008). The
E1 component subunit α of the pyruvate dehydrogenase (PDH)
complex (BA4184), has also been identified as a significant,
immunogenic B. anthracis protein previously by other workers
(Liu et al., 2013). This would suggest that similarly pdhC may be
involved in pathogenicity during Anthrax infection.
There is also clear differential recognition of protein
features between the two “infected” groups, perhaps indicating
dissimilar disease presentation and/or progression pathways
and thus differential protein/pathway expression on the part
of the infectious agent in response to differing environmental
stress/stimuli. These may perhaps constitute proteins from
differentially regulated pathogenicity “regulons.” Like other
bacteria B. anthracis is found to differentially regulate its
transcriptional and hence, by inference, its protein repertoire
in response to external environmental stimuli (Carlson et al.,
2009). Some of these e.g., BA3828 and BA0391 are transcription
factors which are differentially regulated between the two groups.
The former is specific to the TCA group and the latter the AP
IVDU group. These merit further follow up as they may be of
significance in pathogenicity and involved in development of
the different clinical disease presentations observed in patients.
Similar studies have been conducted previously however the
complement of proteins presented in this study do not share
antigen features in common (Kudva et al., 2005; Pflughoeft et al.,
2014).
Good recognition of PA and LF was observed for all the
vaccinated and infected/challenged groups, however recognition
of EF was only observed in the AVPV group for IgG and weakly
by the BWS and AN IVDU groups. Some weak recognition of
EF was seen with the control group. IgA recognition of EF was
seen mainly with the AVPV and TCA and more weakly for the
BWS and AN IVDU groups. Again, some weak IgA recognition
of EF was seen with the control group. Thus, despite the fact that
edema is a common feature of disease in the TCA and particularly
the AP IVDU group, little significant antibody response is seen to
this toxin component in the infected groups. The IgG anti-toxin
response is more marked in the AVPV group, although some
IgA reactivity is also seen, however the predominant anti-toxin
response in the AP IVDU and TCA infected groups is with IgA.
These observations are confirmed from comparative rabbit live
spore and AVP vaccination model data. The anti-toxin response
in AVP vaccinated rabbits is biased toward IgG, whereas the anti-
toxin response in spore vaccinated rabbits is biased toward IgA.
Regulation of the IgA response although not fully understood
may be via invariant natural killer T (iNKT) (MacLeod et al.,
2013; Zeng et al., 2013) or gamma delta T cells (Fujihashi et al.,
1996; Tezuka et al., 2011). This may perhaps imply involvement
of these cell types during active B. anthracis infection. The means
by which live spore challenge elicits this IgA-biased response
strongly merits further investigation.
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Although immunogenic proteins other than the toxin
components were identified in this study, some of which appear
to be specifically recognized by certain groups, none appeared
to be B. anthracis specific and of a size amenable to chemical
synthesis for further analysis. We therefore investigated the
repertoire of conserved hypothetical and hypothetical proteins
represented in the B. anthracis genome using the database
comparison tool BLAST. Five proteins were identified of a
size amenable to chemical synthesis, two of which exhibited
B. anthracis specificity, two exhibiting partial protein sequence
similarity and one exhibiting sequence conservation with other
closely related bacillus species. These were used in ELISAs to
determine their antibody reactivity with the control, AVPV, TCA,
and AP IVDU groups in comparison to PA and LF as positive
controls. Only BA0448 exhibited IgG reactivity in the AP IVDU
group. The R value for this antigen was less than that observed
for LF and greater than that for PA, indicating that this peptide
and LF would be more useful for diagnostic detection in the
AP IVDU group than PA for IgG. However, all five peptides
exhibited good reactivity for IgA for the AP IVDU and TCA
groups and four of five for the AVPV group. This indicates that all
five are recognized by infected individuals, suggesting that they
are expressed during infection and four of five are recognized
by vaccinees indicating that they are present in the UK AVP
vaccine. The R-values for the AP IVDU group were higher than
that for either PA or LF, indicating that all five peptides are
recognized with good specificity by this infected group andwould
be useful in a diagnostic context. All peptides exhibited poorer
specificity for the TCA and also the AVPV groups than the
toxin components, based on R-values. Therefore, four of the five
proteins appear to be expressed both during vegetative growth
in vitro and during infection; whereas BA2182 is not recognized
by the AVPV group so may be more specifically expressed during
infection only.
Little is known about the function of these peptides other
than for BA4898 which is a spore associated protein and is
associated with the exosporium. The expression profile or the
function of the other four hypothetical proteins either in vitro
or vivo is unknown; however their recognition by immune sera
would suggest they are actively expressed by B. anthracis cells.
There are a very large number of (1) conserved hypothetical
and (2) hypothetical proteins in the B. anthracis genome and
pXO1 and pXO2 plasmids. In this study we observed that
across all groups (1) 51.13% of the genomic and 63.64% of the
plasmid conserved hypothetical proteins and (2) 52.74% of the
genomic and 64.66% of the plasmid hypothetical proteins were
recognized as statistically significant by IgG binding. Whereas,
(1) 27.57% of the genomic and 18.18% of the plasmid conserved
hypothetical proteins, and (2) 19.19% of the genomic and 10.53%
of the plasmid hypothetical proteins were recognized by IgA
of these entities featured on the array (data not shown). This
demonstrates that a large number of these may be expressed
in vitro and in vivo and are recognized by both IgG and IgA. They
also exhibit broadly group specific recognition profiles. It also
parallels the expression distribution data which show a narrower
range of recognition of proteins by IgA than for IgG. These
peptides may be of great value in differential diagnosis of Anthrax
infection, however as they were found not to be immunogenic
in a mouse vaccination study their use as vaccine or vaccine
components is uncertain. Perhaps in combination vaccines with
other proteins or adjuvants they may be immunogenic, but
they proved non-immunogenic as single peptide entities in this
study.
In summary, the Anthrax ProtoArray has identified many
immunogenic proteins in both vaccinated and Anthrax
challenged groups. However, overall recognition of Anthrax
proteins was somewhat more reduced than expected in the
challenged groups when compared to naive controls. Of the
proteins recognized by the vaccinated and Anthrax challenged
groups, the toxins proved the most immune-dominant both for
IgG and IgA recognition. Other proteins were also recognized
in challenged groups which were not recognized by controls,
some of which exhibited group specificity. These may be due to
differing recognition related to specific infection or challenge
routes or by differential expression of protein “infectome” by
the Anthrax bacillus in response to different environmental
stimuli. Further work is required to determine the underlying
immunopathological basis for the IgA biased protein recognition
and also the apparent IgG immunosuppression observed in the
infected groups, and to determine the function of the identified
proteins in bacterial pathogenesis and their potential utility as
diagnostic or vaccine targets.
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